Johnson & Johnson has finalized its acquisition of Halda Therapeutics OpCo, Inc., a biotechnology company focused on developing targeted therapies for solid tumors. The deal, valued at $3.05 billion in cash, brings Halda’s Regulated Induced Proximity Targeting Chimera (RIPTAC) platform into Johnson & Johnson’s oncology portfolio.
Jennifer Taubert, executive vice president and worldwide chairman of Innovative Medicine at Johnson & Johnson, said, “This strategic milestone underscores our commitment to redefining cancer treatment with breakthrough science and transformative medicines. We are excited to formally welcome the talented Halda team to Johnson & Johnson and look forward to working together to achieve our shared goal of eliminating cancer.”
Through this acquisition, Johnson & Johnson gains HLD-0915, an oral therapy in clinical development for prostate cancer. The company also adds several early-stage candidates targeting breast, lung, and other tumor types using the RIPTAC technology. According to the announcement, this technology may enable the creation of new targeted therapies beyond oncology.
John C. Reed, M.D., Ph.D., executive vice president of Innovative Medicine R&D at Johnson & Johnson stated: “Johnson & Johnson continuously seeks new ways to meet patient needs and deliver innovative therapies. Now that we have finalized this acquisition, we will focus on advancing the potential of this promising pipeline of novel product candidates and harnessing the powerful RIPTAC platform to discover more molecules in oncology and beyond.”
The transaction will be accounted for as a business combination. With the closing set for 2025, Johnson & Johnson anticipates a dilution in earnings per share by approximately $0.20 split between Q4 2025 and 2026 due to costs related to employee equity awards from Halda as well as financing and integration expenses. Further guidance for full-year 2026 is expected during the company’s fourth quarter earnings call scheduled for January 21, 2026.
